Eden Research PLC, an AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology, has confirmed the grant of options under the Company's Long Term Incentive Plan to its Chief Executive Officer, Sean Smith, and Chief Finance Officer, Alex Abrey. The grant includes options over 11,918,901 new Ordinary Shares in Eden, at a strike price of 6.5p each, representing a premium of 48% to the current share price. The Options expire on 30 June 2028 and vest over a period of 36 months from the date of grant.

Sean Smith has been awarded 6,805,852 options, while Alex Abrey has been awarded 5,113,049 options. The notifications have been made in accordance with the requirements of the EU Market Abuse Regulation. The options are aimed at ensuring the continuity of long-term incentives for the executives. For further information, interested parties can contact Eden Research PLC directly.

The options were granted outside of the trading venue and are in line with the Company's focus on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health, and consumer products industries. This move is in line with the Company's commitment to incentivize and retain key executives to drive the company's long-term success.